

R H I N O M E D

RHINOMED APPOINTS CFO, CONSOLIDATES AUSTRALIAN DISTRIBUTION.

Key Highlights:

- Executive team changes
- Resumes control of wholesaling and distribution in Australia and New Zealand

November 29th 2018. Melbourne, Australia

Rhinomed Limited (ASX: RNO), a nasal delivery technology company, wishes to advise investors of several significant points of progress and updates that are occurring within the business globally and are designed to address its growing business momentum.

Appointment of CFO

The company is pleased to advise that it has appointed Mr Sean Slattery as Chief Financial Officer. Mr Slattery is an experienced financial executive with over 20 years of experience in senior financial roles including as a director, company secretary and Chief Financial Officer of both private and ASX listed companies.

Mr Slattery's previous roles have included being CFO at Unscriptd Ltd, Powerwrap Ltd and Accendre Pty Ltd. He was also Financial Director Asia Pacific for Cybertrust Australia now part of Verizon. Mr Slattery has a Master of Taxation from University of Melbourne, is a Member of the Institute of Chartered Accountants and completed his Bachelor of Science from Salisbury University in Maryland, USA.

Michael Johnson, Rhinomed CEO, commented, *"The company has grown rapidly over the last 12 months and our increasing multijurisdictional (US, UK and Australia) operational focus has required we add a key player with global financial experience and operational excellence to the team. We are delighted to welcome Sean as we move to the next exciting chapter of Rhinomed's journey."*

The company can also advise that Mr Shane Duncan VP Sales and Marketing Americas is returning to Australia and as a result will leave the company to pursue other opportunities. The company's major US based accounts will continue to be managed by the USA based key account teams in place.

Michael Johnson, CEO said, *"Shane has helped spear our entry in the USA and built a strong team on the ground to support our 9000+ store network. While we are sad to see him go, he leaves the Rhinomed US team well positioned to exploit our growing presence in the US."*

R H I N O M E D

Australian Distribution Change

Following an internal review of this Australian and New Zealand program, Rhinomed is resuming control of wholesaling and distribution of Mute that was previously conducted by BOC in the Australian and New Zealand markets. We thank BOC for their interest in the Mute technology over the last two years.

All existing retail and wholesaling accounts will be serviced by Rhinomed directly and, as a result, the company expects a positive impact on Q3 and Q4 revenues.

US Office relocation

The company will be moving its office from Cincinnati to New York in early 2019. This move coincides with the increase in activity with new medical marijuana licensing partner Columbia Care, as well as the planned growth in US based consumer health market.

Media Enquiries

Michael Johnson, CEO & Director

+61 (0) 3 8416 0900

mjohnson@rhinomed.global

www.mutesnoring.com

Follow us on **Twitter** @rhinomedceo and @mutesnoring

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global